Related Experiment Video
Updated: Aug 8, 2026
08:49
Models of Bone Metastasis
Published on: September 4, 2012
Biochemical bone markers in breast cancer
1Division of Oncology, Room C6830, Hershey Medical Center, Hershey, PA 17033, USA. alipton@psu.edu
Cancer Treatment Reviews
|May 9, 2006
Summary
Identifying patients at risk for bone metastases is crucial for effective treatment. New biochemical markers show potential for predicting bone metastases and guiding bisphosphonate therapy, especially in breast cancer management.
Area of Science:
- Oncology
- Orthopedics
- Biochemistry
Background:
- Bone metastases are a common complication of advanced cancers like breast and prostate cancer, causing significant pain and disability.
- Bisphosphonates are effective in managing metastatic bone disease (MBD), but identifying patients who will benefit remains a challenge.
- Understanding the pathophysiology of bone metastases has led to the identification of potential biochemical markers for bone coupling dysregulation.
Purpose of the Study:
- To validate newly discovered biochemical markers for their ability to predict the development of bone metastases.
- To explore the utility of these markers in assessing the efficacy of bisphosphonate treatment and other therapies for MBD.
- To investigate the specific relevance of these markers in the context of breast cancer management.
Main Methods:
- Clinical trials were conducted to validate potential biochemical markers associated with bone metastases.
- Studies focused on assessing the correlation between marker levels and the incidence of bone metastases.
- Research explored the use of these markers in monitoring treatment response to bisphosphonates and other bone-targeting therapies.
Main Results:
- Recent trials indicate a correlation between certain biochemical markers and the development of bone metastases.
- These markers show potential in identifying patients who may benefit from early intervention and bisphosphonate therapy.
- Preliminary results suggest these markers could aid in evaluating treatment effectiveness for metastatic bone disease, particularly in breast cancer.
Conclusions:
- Biochemical markers for bone turnover show promise in identifying patients at risk for bone metastases.
- Further research is necessary to clarify the definitive role and clinical utility of these markers in MBD management.
- These markers may offer a valuable tool for personalized treatment strategies, especially in breast cancer patients with bone metastases.
